Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 7;10(9):2909-2911.
doi: 10.1016/j.ekir.2025.06.057. eCollection 2025 Sep.

Reassessing Rituximab in Membranous Nephropathy: Efficacy, Limitations, and the Path Ahead

Anne-Els van de Logt  1 , Jack F M Wetzels  1
Affiliations
Editorial

Reassessing Rituximab in Membranous Nephropathy: Efficacy, Limitations, and the Path Ahead

Anne-Els van de Logt et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Algorithm of individualized therapy in PLA2Rab associated membranous nephropathy. ∗Negative: IFT negative or ELISA PLA2Rab < 2RU/ml. 1-8For detailed information please refer to the test in the Supplementary material. APRIL, A proliferation-inducing ligand; BAFF, B-cell activating factor; CP, cyclophosphamide; ELISA, enzyme-linked immunosorbent assay; IFT, immunofluorescence; MN, membranous nephropathy; PLA2Rab, antiphospholipase A2 receptor antibody; Pred, prednisolone; RTX, rituximab.
See this image and copyright information in PMC

Comment on

References

    1. Rovin B.H., Adler S.G., Barratt J., et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:753–779. doi: 10.1016/j.kint.2021.05.015. - DOI - PubMed
    1. Vargas-Brochero M.J., Lafaut E., Radhakrishnan Y., et al. Long-term outcome of adult patients with membranous nephropathy treated with rituximab. Kidney Int Rep. 2025;10:2630–2641. doi: 10.1016/j.ekir.2025.05.013. - DOI - PMC - PubMed
    1. Cattran D.C., Kim E.D., Reich H., Hladunewich M., Kim S.J., Toronto Glomerulonephritis Registry group Membranous nephropathy: quantifying remission duration on outcome. J Am Soc Nephrol. 2017;28:995–1003. doi: 10.1681/ASN.2015111262. - DOI - PMC - PubMed
    1. Ruggenenti P., Debiec H., Ruggiero B., et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26:2545–2558. doi: 10.1681/ASN.2014070640. - DOI - PMC - PubMed
    1. Dahan K., Debiec H., Plaisier E., et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2016;28:348–358. doi: 10.1681/ASN.2016040449. - DOI - PMC - PubMed

LinkOut - more resources